+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 29 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.

Age: 18Years +FEMALEPhase 3
206 locations
P

Actively Recruiting

Researchers are evaluating VVD-130037, a Kelch-like ECH Associated Protein 1 KEAP1 activator, in adults with advanced solid tumors in a first-in-human study. The study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and early anti-tumor activity of VVD-130037, both alone and combined with other cancer treatments. This is an open-label, phase 1 trial sponsored by Vividion Therapeutics, Inc., focusing on patients whose cancer has progressed despite prior standard therapies. Participants receive escalating doses of VVD-130037 orally once or twice daily in 21- or 28-day treatment cycles. In Part 1 dose escalation, VVD-130037 is tested alone and combined with intravenous docetaxel, paclitaxel, or pembrolizumab at established schedules. Part 2 dose expansion administers VVD-130037 at the recommended dose for expansion RDE, alone or in combination, to further evaluate safety and activity. Treatment cycles vary by combination, with docetaxel given every 3 weeks and paclitaxel given on days 1, 8, and 15 of each cycle. Participants undergo regular assessments including monitoring for dose-limiting toxicities during the first treatment cycle and tracking adverse events over up to 4 years. Laboratory tests, electrocardiograms, and imaging evaluations measure drug concentrations, heart rhythm, and tumor response. Researchers also evaluate overall response rates, duration of response, progression-free survival, and disease control rates. Safety follow-up and detailed pharmacokinetic studies are part of the long-term observation to understand the effects of VVD-130037 and its combinations.

Age: 18Years +All GendersPhase 1
26 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining immunotherapy with radiotherapy compared to immunotherapy alone for patients with advanced hepatocellular carcinoma HCC that involves major blood vessels. This Phase II study focuses on patients with unresectable or metastatic disease showing major vascular invasion, aiming to improve treatment outcomes for this serious liver cancer. The trial includes two treatment groups one receiving immunotherapy combined with proton beam radiation therapy, and the other receiving immunotherapy alone. The radiation dose and schedule are tailored by physicians based on normal tissue safety. Participants receive these treatments concurrently as part of the study interventions. Participants will be monitored for progression-free survival over about three years along with other outcomes like overall survival, time to progression, and response rates. The study involves regular assessments including imaging to measure tumor response and safety evaluations. This helps researchers track both treatment effects and any side effects throughout the study period.

Age: 19Years +All GendersPhase 2
2 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of IMC-001 in patients with metastatic or locally advanced TMB-High TMB-H solid tumors. This Phase 2 study aims to determine how well IMC-001 works in this specific group of cancer patients, focusing on those with tumors that have a high tumor mutational burden. The trial is sponsored by ImmuneOncia Therapeutics Inc. and seeks to understand the drugs impact on tumor response and patient survival. All participants receive IMC-001 through an intravenous infusion at a dose of 20 mgkg every two weeks, administered over 60 minutes. Treatment can continue for up to 2 years, with each treatment cycle lasting 14 days. Imaging scans to monitor tumor response are performed every 6 weeks during treatment and follow-up, including after the end of treatment. The study includes a safety follow-up visit 28 days after the last dose. Participants will be closely monitored with imaging every 6 weeks to assess tumor changes, progression-free survival, duration of response, and overall survival over an average of one year. Additional assessments include pharmacokinetic and immunogenicity evaluations. The study requires regular visits for treatment, scans, and follow-up, with maximum treatment duration of 2 years. Safety and response data are collected throughout the study period until disease progression or initiation of other treatments.

Age: 19Years +All GendersPhase 2
4 locations
R

Actively Recruiting

Researchers are evaluating IMVT-1402, a drug being studied for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug treatment. This Phase 2b, randomized, double-blind, placebo-controlled study aims to assess the drugs efficacy, safety, and tolerability in a global, multi-center setting. Participants are assigned to receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study compares these groups to see how well IMVT-1402 helps participants become euthyroid normal thyroid function and stop antithyroid drugs. The two doses are given over the same 26-week period, with monitoring at several time points. During the trial, participants will undergo regular evaluations including thyroid hormone measurements such as triiodothyronine T3 and free thyroxine FT4. Researchers will measure how many participants achieve normal thyroid hormone levels and are off antithyroid drugs by Week 26. Safety and tolerability are also monitored throughout. The main outcome is the percentage of participants who are euthyroid and off antithyroid drugs at Week 26, with follow-up assessments planned for this duration.

Age: 18Years - 75YearsAll GendersPhase 2
163 locations
R

Actively Recruiting

Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.

Age: 12Years +All GendersPhase 3
316 locations
P

Actively Recruiting

Researchers are studying the effects of NGM120 in people with colorectal cancer who also have cancer cachexia, a condition involving significant weight loss. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to assess the safety, tolerability, and potential benefits of NGM120 in this population. Participants will receive either NGM120 or a placebo through subcutaneous injections. NGM120 is given in different dosing schedules low dose every 4 weeks, high dose every 4 weeks, or high dose every 8 weeks. Placebo is administered every 4 weeks. These treatments will be compared to evaluate differences. Throughout the study, participants body weight changes will be monitored for 12 weeks to assess treatment impact. Safety will be evaluated by tracking adverse events over 44 weeks. Participants will undergo regular assessments, including monitoring for treatment effects and side effects, with the total study duration extending up to 44 weeks.

Age: 18Years +All GendersPhase 2
28 locations
L

Actively Recruiting

Researchers are evaluating the effect of low-dose aspirin 100 mg daily on preventing gastric cancer in patients with early gastric cancer or high-grade adenoma who have undergone endoscopic resection and have a negative or eradicated Helicobacter pylori status. This randomized, placebo-controlled Phase 3 trial addresses limitations in previous studies by focusing specifically on gastric cancer prevention with appropriate sample size and follow-up. Aspirin is commonly used to reduce cardiovascular risks, and some evidence suggests it may also lower gastrointestinal cancer risk, but more targeted research is needed. Participants will be randomly assigned to receive either enteric-coated aspirin 100 mg daily or a placebo tablet for five years. This double-blind study compares the incidence of gastric cancer between the aspirin and placebo groups. The trial includes a treatment period of five years, during which participants take the assigned medication daily. The study also monitors secondary outcomes like mortality, cardiovascular events, occurrence of other cancers, gastric dysplasia, aspirin-related complications, and gastric tissue improvements. During the study, participants will undergo regular assessments including pathology reviews after endoscopic resection and monitoring for adverse events. Researchers will track the primary outcome of gastric cancer incidence throughout the treatment period. Secondary outcomes such as cardiovascular disease rates and overall survival will also be evaluated. The total participant involvement includes screening, a five-year medication period, and ongoing monitoring to assess treatment effects and safety.

Age: 19Years - 70YearsAll GendersPhase 3
10 locations
E

Actively Recruiting

Researchers are evaluating zongertinib, an oral HER2-targeted drug, to see if it can improve outcomes compared to standard adjuvant treatments in adults with completely removed Stage II to IIIB non-small cell lung cancer NSCLC that has activating HER2 tyrosine kinase domain mutations. This Phase 3, global, randomized, open-label study includes participants who have had surgery with curative intent and received perioperative systemic therapy such as neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomly assigned to one of two groups one group takes zongertinib daily by mouth for up to three years, while the other group follows standard care, which may include approved adjuvant immunotherapy or observation based on local guidelines and patient condition. This comparison aims to determine if zongertinib can extend disease-free survival. Safety, overall survival, tolerability, and patient-reported outcomes are also monitored during the study. During the study, participants undergo regular evaluations including disease assessments by investigators for up to 8 years and 5 months to measure disease-free survival and overall survival. Safety is tracked by recording adverse events, especially those of grade 3 or higher, from treatment start through up to three years or tumor recurrence. Participants provide tumor tissue samples for HER2 status confirmation, and their overall health and organ functions are monitored. The entire study lasts several years, including follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
203 locations
S

Actively Recruiting

Researchers are evaluating BOLD-100, an intravenous ruthenium-based small molecule drug, in combination with FOLFOX chemotherapy with or without Bevacizumab for treating advanced gastrointestinal cancers such as colorectal, pancreatic, gastric cancers, and cholangiocarcinoma. This Phase 1b2a non-randomized study includes a dose escalation phase to assess safety and tolerability, followed by a cohort expansion phase focusing on patients with advanced solid tumors. The study aims to understand BOLD-100s potential when combined with standard chemotherapy regimens. Participants receive BOLD-100 combined with FOLFOX chemotherapy, with or without Bevacizumab, in different dose levels including 500 mgm2 and 625 mgm2. The study includes multiple arms, some closed to enrollment and others open to patients with colorectal cancer who are oxaliplatin naive and have had only one prior metastatic treatment. Participants are randomized in Arm VII to receive one of two doses of BOLD-100 plus FOLFOX Bevacizumab or FOLFOX Bevacizumab alone. Throughout the study, participants undergo assessments for adverse events, dose-limiting toxicities, physical exams, ECGs, laboratory tests, and performance status. Quality of life questionnaires focusing on general and neuropathy-related aspects are completed by those in Arm VII. Researchers measure progression-free survival, overall response rate, and overall survival. The study also monitors pharmacokinetics and biomarkers during treatment. Participation continues until approximately two weeks after the last treatment, with ongoing safety and efficacy evaluations.

Age: 18Years +All GendersPhase 1Phase 2
28 locations

1-10 of 29

1